We See Value in Vertex
A strong competitive position in the cystic fibrosis market gives the firm a narrow moat.
Vertex Pharmaceuticals' (VRTX) stock price has declined significantly in recent months as a result of worries about the sustainability of drug pricing and, in particular, concerns about the launch trajectory of the firm's soon-to-be blockbuster cystic fibrosis drug Orkambi. However, we think the company's value has become more compelling as the launch of Orkambi takes hold and its portfolio of cystic fibrosis drugs positions Vertex to dominate this lucrative rare-disease market and achieve probability-adjusted peak sales of over $6 billion. Vertex's strong competitive positioning in the cystic fibrosis market is the basis of our narrow economic moat rating. The firm enjoys strong pricing power for its drugs (six-figure annual pricing for the chronic disease), extended patent protection (until at least 2027), and a welcoming commercial and regulatory environment due to severe unmet medical need. Competition is increasing, but it remains early-stage, unproven, and unlikely to displace Vertex's growing franchises.
Vertex was once best known for discovering Incivek, a blockbuster hepatitis C virus drug; however, with that drug's sales disappearing because of increased competition in the HCV market, the firm's future is now tied to its burgeoning cystic fibrosis portfolio. Approved treatments Kalydeco and Orkambi and additional pipeline assets are expected to create a dominant franchise in this lucrative rare-disease market.
Stefan Quenneville, CFA does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.